Efficacy and safety of two weeks rabeprazole treatment for gastric ulcers after endoscopic submucosal dissection (ESD).
Not Applicable
- Conditions
- early gastric cancer or gastric adenoma
- Registration Number
- JPRN-UMIN000000688
- Lead Sponsor
- The University of Tokyo, Department of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients whose lesions were diagnosed as: depth more than sm2, resected margin positive of tumor, lesions with ulcer, tumor with diffuse type cancer. 2. Patients who required surgical intervention after ESD. 3. Patients with 2 or more lesions. 4. Patients who are allergic to PPI. 5. Patients with serious comorbid diseases. 6. Patients taking NSAIDs, steroid, anticoagulants and antiplatelets. 7. Patients who were judged inappropriate by their physicians.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of ulcers in scarring stage at 8 weeks after ESD.
- Secondary Outcome Measures
Name Time Method Incidence of post-operative bleeding and abdominal symptoms.